Should I buy Pfizer stock in 2025 as a Philippine investor?

What is Pfizer?

How much is Pfizer stock?

The price of Pfizer stock is rising this week. As of now, Pfizer shares are trading at $23.32, up 1.22% over the last 24 hours and 2.15% for the week. The company holds a substantial market capitalization of $132.58 billion, with an average daily volume of 54.76 million shares over the past three months.

With its attractive dividend and moderate risk profile, Pfizer remains a compelling option for income-seeking investors in the Philippine market.

Our full analysis on Pfizer stock

Following a rigorous assessment of Pfizer’s most recent quarterly earnings and a detailed review of the stock’s performance over the past three years, our proprietary analytical framework has synthesized diverse inputs—including core financial metrics, technical indicators, market sentiment, and competitive positioning. The result is a robust, multidimensional perspective on one of the world’s most influential pharmaceutical giants. So, why might Pfizer stock once again become a strategic entry point within the healthcare sector in 2025?

Recent Performance and Market Context

2025 finds Pfizer at a pivotal juncture. While the company’s shares currently trade at $23.32—having shed 18.72% over the past year and 9.08% over the last six months—this apparent correction masks a more dynamic underlying narrative. Notably, the past week has seen a moderate inflection, with a 2.15% gain and a 1.22% advance in the last 24 hours, suggesting the beginning of a positive technical momentum shift. This improved sentiment can be linked to Pfizer’s solid Q1 2025 results: an adjusted diluted EPS of $0.92, which exceeded consensus estimates, and robust operational growth in several core product lines.

The broader pharmaceutical sector has maintained its defensive appeal amid macroeconomic uncertainty, with healthcare stocks across US and Asian markets demonstrating resilience. For investors in the Philippines, US blue chips like Pfizer offer exposure to both currency diversification and the steady innovation pipeline of an established sector leader. The sector’s favorable macroeconomic backdrop—driven by continued demand for advanced therapeutics, demographic tailwinds, and the ongoing global recalibration of healthcare priorities—positions Pfizer for renewed interest as market volatility persists.

Further underpinning investor confidence, Pfizer has reaffirmed its full-year revenue and profit guidance despite lingering declines in COVID-19-related product sales. Management’s swift implementation of a $4.5 billion cost realignment program and commitment to sustaining high R&D investment reflect both operational discipline and a deliberate focus on long-term value creation.

Technical Analysis

Pfizer’s technical landscape points to an evolving story of gradual recovery. After a prolonged period of underperformance, recent price action indicates constructive near-term changes, especially worth noting:

• Moving Averages: The current share price is above both the 20-day EMA ($22.92) and 20-day SMA ($22.98)—a bullish signal for investors watching short-term trends. Additionally, the price is above the 50-day SMA ($23.27), suggesting sustainable momentum is building. The stock remains below longer-term averages (100-day and 200-day levels), underlining that it is still in a transitional phase—a potential opportunity for investors anticipating a technical reversal.
• Oscillators: Neutral readings across RSI (51.53), CCI (6.49), and Stochastic %K (54.39) indicate the stock is neither overbought nor oversold, leaving ample room for additional upward movement. Importantly, the MACD is forming a bullish crossover, further strengthening the case for an impending upward swing.
• Support and Resistance: Strong support at $22.87, with immediate resistance at $23.65 and $24.10. Should the price definitively breach these resistance levels, it would likely validate the emerging bullish scenario, providing investors with clear technical entry points.

Together, these signals paint an encouraging technical setup: one that suggests Pfizer may be entering a new bullish phase, with market structure favorably positioning the stock for medium-term appreciation.

Fundamental Analysis

From a fundamental perspective, Pfizer’s current valuation and strategic positioning argue strongly in favor of renewed consideration from discerning investors:

• Revenue and Profitability: While Q1 2025 revenue ($13.7 billion) reflected an 8% year-on-year decrease—largely attributed to post-pandemic normalization—core franchises continue to deliver impressive growth. Notably, products like the Vyndaqel family (+33%), Comirnaty (+62%), Nurtec ODT/Vydura (+40%), Padcev (+25%), and Lorbrena (+39%) illustrate the entrepreneurial dynamism of Pfizer’s diversified portfolio.
• Attractive Valuation: Pfizer’s forward P/E ratio of 7.99 stands out as notably attractive compared with industry averages, and the PEG ratio of 0.59 signals undervaluation relative to its expected earnings trajectory. The price-to-sales ratio (2.13) and price-to-book (1.47) further highlight a compelling value proposition, especially in relation to other large-cap peers.
• Dividend Yield: A 7.38% dividend yield, supported by a strong balance sheet and disciplined capital allocation, positions Pfizer as a particularly appealing choice for income-oriented investors seeking stability and consistent returns.
• Structural Strengths: The company’s global scale, deep R&D capabilities, operational efficiency initiatives, and unrivaled brand equity provide substantial competitive moats in an intensely innovative sector. Furthermore, Pfizer’s commitment to core areas such as oncology, immunology, rare diseases, and vaccines ensures a future-oriented growth trajectory.
• Cost Optimization: The ambitious $4.5 billion cost savings target by the end of 2025, coupled with a further $1.2 billion identified by 2027, not only counteracts recent revenue headwinds but also sets the stage for improved margins and long-term value creation.

Collectively, these factors paint a picture of a company in the midst of a multi-year transformation, where the fundamentals more than justify renewed investor interest at current price levels.

Volume and Liquidity

Pfizer’s role as a global blue chip is confirmed by sustained high trading activity, averaging 54.76 million shares daily over the last three months. This liquidity ensures efficient price discovery and ease of entry and exit for all classes of investors—from individual traders in the PH market to institutional allocators. The ample public float (5.68 billion shares) encourages continued market participation and minimizes bid-ask spreads, supporting dynamic valuation re-ratings as sentiment evolves. Steady, substantial volume patterns are often a sign of underlying market conviction—an important signal for those considering accumulation ahead of the next potential leg upward.

Catalysts and Positive Outlook

Looking forward, several key catalysts and strategic themes are poised to underpin Pfizer’s potential outperformance:

• Product Pipeline: With $2.2 billion invested in R&D in Q1 2025 alone, Pfizer demonstrates a sustained commitment to innovation. Multiple late-stage assets—particularly in oncology, rare diseases, and next-generation vaccines—have the capacity to drive major future revenue streams. Strong recent performances by products outside the COVID-19 franchise reinforce the notion of an increasingly resilient portfolio.
• Cost Realignment: Execution of the company’s multi-year cost-saving program is set to expand operating margins and enhance profitability, even in a flat or slightly negative top-line environment.
• Shareholder Returns: With one of the most attractive dividend yields among global majors and a strong history of consistent payouts, Pfizer meets the needs of both growth- and income-focused investors.
• ESG and Sustainability: Pfizer’s long-standing leadership in responsible practices—from improving access to essential medicines to pioneering sustainable production—remaining central to its brand and a positive driver of investor sentiment.
• Analyst Consensus: Market consensus continues to tilt positively: a median price target of $29.50 implies a 26% upside from current levels, indicating substantial confidence in the company’s recovery and medium-term strategic plan.
• Sector Tailwinds: Broader healthcare trends—such as aging populations, the increasing prevalence of chronic diseases, and sustained investment in pharmaceutical innovation—provide powerful sectoral support. Regulatory changes in Asia and ongoing upgrades in PH healthcare systems further enhance the relevance of large, diversified players like Pfizer.

Taken together, these factors create a favorable context in which Pfizer’s undervalued shares could enter a period of outperformance, supported by both company-specific and macroeconomic catalysts.

Investment Strategies

Pfizer presents compelling arguments for several investor profiles and strategic time horizons:

• Short-term: Technical momentum is beginning to improve, with bullish signals from moving averages and an emerging MACD crossover. Investors anticipating a continued technical recovery can capitalize on price appreciation as the stock approaches key resistance zones.
• Medium-term: Building positions ahead of upcoming earnings, major product launches, or strategic updates could be advantageous, as the combination of operational efficiency measures and R&D milestones often act as share price catalysts.
• Long-term: For investors with a preference for stability, income, and value, Pfizer’s current yield and attractive valuation metrics argue for a buy-and-hold approach. Potential upside will be driven by the materialization of cost savings, pipeline progress, and sector-wide demographic tailwinds.

In terms of tactical positioning, accumulation near current support levels ($22.87–$23.32) provides downside protection and a favorable risk/reward setup, especially when layered with a focus on forthcoming product and pipeline news.

Is It the Right Time to Buy Pfizer?

After a period of transition, Pfizer’s stock appears to be entering a new phase with several compelling strengths:

• Attractive valuation ratios (forward P/E of 7.99, PEG of 0.59) relative to both historical standards and sector peers.
• Among the highest dividend yields in its class, appealing to income and value investors alike.
• Technical indicators suggest potential bottoming and the beginning of a new bullish phase.
• Operational discipline and cost initiatives are clearly driving improved productivity and margin potential.
• Robust innovation pipeline and expanding growth products beyond the COVID-19 portfolio.
• Strong global brand, market presence, and sustainable R&D commitment.
• High trading liquidity and institutional participation signal continued market interest.

While no investment is without risks—notably continued headwinds in COVID-19 product revenues and regulatory uncertainty—the risk/reward balance for Pfizer at current price levels seems decisively tilted towards upside potential. As the company leverages its innovation engine, captures operational efficiencies, and benefits from a resilient sector backdrop, the fundamentals and technicals alike justify a renewed, confident consideration of Pfizer as a portfolio cornerstone—especially for PH-based investors seeking diversification and long-term growth opportunities in global healthcare.

For those prepared to look beyond recent turbulence, Pfizer currently seems to represent an excellent opportunity to participate in the recovery and renewed growth of a global pharmaceutical leader—a conviction grounded in clear fundamentals, robust technical structure, and a future-oriented strategic vision.

How to buy Pfizer stock in PH?

Buying Pfizer (PFE) shares online is now straightforward and secure for retail investors in the Philippines, thanks to modern, regulated brokers operating globally. You can invest in Pfizer either by direct “spot” purchases (actual shares, held in your name) or via contracts for difference (CFDs), which allow you to speculate on price movements with leverage but without owning the underlying stock. Both methods offer flexibility, but it’s important to understand the differences. To help you make the best choice, a detailed comparison of leading brokers for Philippine investors is available further down this page.

Spot Buying

A spot (or cash) purchase means you buy real Pfizer shares, making you a part-owner eligible for potential dividends and shareholder rights. You pay the full amount for the shares up front, plus typical brokerage fees—which often include a fixed commission per order, usually around PHP 250–300 (about $5–6 USD), depending on your broker.

Example

Suppose Pfizer stock is priced at $23.32 per share. With a $1,000 (approx. PHP 56,600) stake, after a $5 brokerage fee, you could purchase about 42 shares ($995 ÷ $23.32 ≈ 42). Gain scenario: If Pfizer’s price increases by 10% to $25.65, your shares are now valued at about $1,100. Result: That’s a $100 gain before any taxes or fees (+10% return).

Spot buying is ideal for investors who want to build long-term wealth and benefit from potential dividends.

Trading via CFD

CFDs (Contracts for Difference) let you trade on the price movements of Pfizer shares without actually owning them, providing the flexibility to go long or short and to apply leverage. Instead of a fixed commission, you typically pay a spread (the difference between buy/sell price) and may incur overnight financing costs if you hold positions for more than a day.

Example

You open a CFD trade on Pfizer with $1,000 capital and 5x leverage, giving you $5,000 in market exposure. Gain scenario: If Pfizer’s price rises by 8%, your position gains 8% × 5 = 40%. So you earn $400 in profit on your $1,000 invested (excluding trading fees or overnight charges).

CFDs can multiply your returns—and losses—so they’re best suited for experienced or more active investors aware of the risks.

Final Advice

Before investing, it’s crucial to compare each broker’s fees, local currency conversion charges, and trading platforms to find what fits your needs and risk profile. Some brokers are better for long-term investing and dividends, while others favor active trading or leverage. Ultimately, your choice depends on your investment objectives and style. To find the platform that’s right for you, check out our comprehensive broker comparison tool further down this page. Happy investing!

Our 7 tips for buying Pfizer stock

The latest news about Pfizer

Pfizer’s stock has risen 2.15% in the past week, showing renewed short-term bullish momentum. The current share price of $23.32 is now trading above both the 20-day exponential and simple moving averages, a technical development that suggests improving sentiment among investors. This is reinforced by a near-neutral but gently improving RSI and a bullish MACD signal in formation, indicating that Pfizer could be at the start of a modest rebound. Such momentum is important for the Philippine market, where global health sector stability is closely watched as a benchmark for healthcare-related investments and ETFs.

Pfizer has maintained its full-year 2025 financial guidance, demonstrating resilience despite declining COVID-19 product sales. The company projects annual revenue between $61.0 and $64.0 billion and adjusted diluted EPS in the $2.80–$3.00 range, underscoring management’s confidence in key growth drivers outside the COVID-19 portfolio. This is particularly relevant for Philippine healthcare institutions and pharmaceutical distributors who depend on a stable supply chain and pricing from leading multinationals, and for investors seeking companies with robust forward planning and cost discipline.

New double-digit growth from products like Vyndaqel, Comirnaty, Padcev, Nurtec ODT/Vydura, and Lorbrena is driving Pfizer’s operational performance. In Q1 2025, these key products recorded operational revenue rises from 25% to as high as 62%, revealing a successful diversification strategy beyond COVID-19 treatments. Philippine patients and providers benefit directly, as several of these medicines, such as Comirnaty (the COVID-19 vaccine), are included in the country’s immunization efforts and advanced therapeutic programs, fostering confidence in the availability and innovation coming from Pfizer’s pipeline.

Pfizer’s sustained 7.38% dividend yield continues to appeal to income-focused investors, including those in the Philippines. With ex-dividend and payment dates confirmed and a low forward P/E ratio of 7.99, the stock not only provides an attractive regular income stream but also signals a potentially undervalued opportunity relative to sector peers. For Filipino investors and institutions, American shares with high yields serve as both diversification and a hedge in uncertain local market conditions, further supported by the presence of tax treaties reducing withholding taxes.

The company’s ongoing cost-saving program and intensified R&D investment underpin its medium-term growth outlook. Pfizer has confirmed a cost realignment initiative aiming for $4.5 billion in annual savings by the end of 2025, with an additional $1.2 billion targeted by 2027, alongside continued R&D spending ($2.2 billion in Q1 alone). Such actions are critical to safeguarding profitability and fostering new drug development—especially vital for emerging markets like the Philippines, where access to innovative therapies depends on the sustained global competitiveness and financial discipline of parent companies like Pfizer.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.